Return to content in this issue

 

Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2: a case description

Pecori D1, Della Siega P1, Sozio E2, Barbano E3, Mazzoran L3, Zanichelli A4, Sbrana F5, Federico I3, Bassi F6, Fabris M7, Vendramin I8, Sbrojavacca R1, Tascini C1

1SOC Malattie Infettive, Azienda Sanitaria Universitaria Integrata di Udine, Udine - Italy
2North-West District, Tuscany Health Care, Spedali Riuniti Livorno, Emergency Department, Livorno – Italy
3Medicina D'Urgenza e Pronto Soccorso, Azienda Sanitaria Universitaria Integrata di Udine, Udine - Italy
4U.O. Medicina Generale, ASST Fatebenefratelli Sacco, Ospedale “Luigi Sacco”, Milano - Italy
5U.O. Lipoapheresis and Center for Inherited Dyslipidemias - Fondazione Toscana Gabriele Monasterio, Pisa, Italy
6SOC Anestesia e Rianimazione 2, Azienda Sanitaria Universitaria Integrata di Udine, Udine - Italy
7Institute of Clinical Pathology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
8Cardiothoracic Department; Division of Cardiac Surgery, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy

J Investig Allergol Clin Immunol 2021; Vol. 31(5)
doi: 10.18176/jiaci.0659


Key words: COVID-19, Icatibant, Severe Acute Respiratory Syndrome, SARS-CoV-2, Contact system

Title Type Size
doi10.18176_jiaci.0659_material-suppl.pdf pdf 422.76 Kb